CAI - NASDAQ
Caris Life Sciences, Inc.
$15.48
-1.5%Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
At a Glance
Live SnapshotCaris Life Sciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Caris Life Sciences, Inc. Income Statement
CAI • NASDAQ
| Caris Life Sciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
812M | 412.3M | 306.1M | 258.5M | 294M | 416.5M | 432.1M | 348.4M | 294.4M | 249.7M | 227.6M | 212.4M | 173.9M | 125.7M | 77.9M | 65.3M | 83.1M | 64.9M | 18.6M | 61.6M | |
GROSS PROFIT | ||||||||||||||||||||
(272.9M) | (233.5M) | (216.8M) | (178.5M) | (109.9M) | (216M) | (218.5M) | (179.1M) | (156.9M) | (123.8M) | (78M) | (67.1M) | (48.4M) | (5.5M) | (6.2M) | (8.7M) | (4.9M) | (4M) | (1.2M) | (0.0) | |
539.2M | 178.8M | 89.3M | 80M | 184.2M | 200.5M | 213.6M | 169.3M | 137.5M | 125.9M | 149.6M | 145.3M | 125.6M | 120.2M | 71.7M | 56.5M | 78.3M | 60.8M | 17.4M | 61.6M | |
OPERATING INCOME | ||||||||||||||||||||
(494.1M) | (435.9M) | (408.9M) | (395.8M) | (45.1M) | (70.2M) | (64.9M) | (63.6M) | (71.5M) | (57.8M) | (52.6M) | (43.9M) | (35M) | (55.9M) | (34.8M) | (33.7M) | (34M) | (20.9M) | (5.4M) | (37.4M) | |
(392.5M) | (321.9M) | (291.5M) | (294.5M) | (27.3M) | (52.7M) | (50.3M) | (42.7M) | (35.7M) | (27.6M) | (0.0) | (19.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(45.3M) | (113.9M) | (116.9M) | (101.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
45.1M | -257.1M | -319.6M | -315.8M | 139.1M | 130.3M | 148.8M | 105.7M | 66M | 68.1M | 97M | 101.4M | 90.6M | 64.3M | 37M | 22.8M | 44.3M | 39.9M | 12M | 24.1M | |
PRE-TAX INCOME | ||||||||||||||||||||
(56.9M) | (50M) | (31.6M) | (26.7M) | (61.6M) | (79.2M) | (78.3M) | (53.1M) | (42.8M) | (36M) | (35.2M) | (36M) | (28.8M) | (16.1M) | (5.3M) | (4.3M) | (9.3M) | (10.4M) | (3.7M) | (7.8M) | |
-40.4M | -42.9M | -20.4M | -25.7M | -61.6M | -79.2M | 0.0 | 0.0 | 0.0 | 0.0 | -35.2M | -36M | -28.8M | -16.1M | -5.2M | -4.3M | -9.1M | -10.3M | -3.7M | -7.8M | |
(56.3M) | (128K) | (500K) | (0.0) | (17.8M) | (17.5M) | (14.5M) | (20.9M) | (35.9M) | (30.2M) | (52.6M) | (24.6M) | (35M) | (55.9M) | (34.8M) | (33.7M) | (34M) | (20.9M) | (5.4M) | (37.4M) | |
-113.2M | -24.8M | -21.9M | -5.1M | -109.6M | 0.0 | -67.3M | -48.5M | -56.1M | -36.9M | -29.5M | -29.8M | -16.5M | -2.4M | -5.2M | -5.4M | -59.7M | -9.6M | -3.7M | -7.8M | |
-68.1M | -281.9M | -341.4M | -320.8M | 29.5M | 55.2M | 81.5M | 57.2M | 9.9M | 31.2M | 67.6M | 71.6M | 74.1M | 61.9M | 31.8M | 17.5M | -15.4M | 30.3M | 8.4M | 16.4M | |
NET INCOME | ||||||||||||||||||||
(469.9M) | (0.0) | (0.0) | (0.0) | (1.8M) | (4.2M) | (2.9M) | -14.9M | (3.8M) | (4.3M) | (7.2M) | (7.1M) | (9.8M) | (11.1M) | (3.6M) | (3.9M) | (11.5M) | (11.1M) | (3.1M) | (6.4M) | |
-538M | -281.9M | -341.4M | -320.8M | 27.7M | 31M | 78.6M | 72.1M | 6M | 26.8M | 60.3M | 63.9M | 63.5M | 50.2M | 28.4M | 13.6M | -27M | 19.2M | 5.2M | 10M |
SEC Filings
CAI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 |
Related Guides
Continue your CAI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.